RHYTHM PHARMACEUTICALS, INC. Retained Earnings
RHYTHM PHARMACEUTICALS, INC. (RYTM) had Retained Earnings of -$1.46 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-04
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.46B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.41B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.35B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$1.30B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.46B 10-Q · filed 2026-08-04 |
| 2026-03-31 | -$1.41B 10-Q · filed 2026-05-05 |
| 2025-12-31 | -$1.35B 10-Q · filed 2026-08-04 |
| 2025-09-30 | -$1.30B 10-Q · filed 2025-11-04 |
| 2025-06-30 | -$1.25B 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$1.20B 10-Q · filed 2025-05-07 |
| 2024-12-31 | -$1.16B 10-K · filed 2026-02-26 |
| 2024-09-30 | -$1.11B 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$1.07B 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$1.04B 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$894.74M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$853.10M 10-Q · filed 2023-11-08 |
| 2023-06-30 | -$808.94M 10-Q · filed 2023-08-01 |
| 2023-03-31 | -$762.24M 10-Q · filed 2023-05-02 |
| 2022-12-31 | -$710.06M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$667.57M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$626.70M 10-Q · filed 2022-08-03 |
| 2022-03-31 | -$581.70M 10-Q · filed 2022-05-03 |
| 2021-12-31 | -$528.94M 10-K · filed 2023-03-01 |
| 2021-09-30 | -$486.07M 10-Q · filed 2021-11-02 |
| 2021-06-30 | -$450.97M 10-Q · filed 2021-08-03 |
| 2021-03-31 | -$415.58M 10-Q · filed 2021-05-03 |
| 2020-12-31 | -$459.33M 10-K · filed 2022-03-01 |
| 2020-09-30 | -$424.43M 10-Q · filed 2020-11-02 |
| 2020-06-30 | -$390.61M 10-Q · filed 2020-08-03 |
| 2020-03-31 | -$359.50M 10-Q · filed 2020-05-04 |
| 2019-12-31 | -$325.33M 10-K · filed 2021-03-01 |
| 2019-09-30 | -$292.38M 10-Q · filed 2019-11-01 |
| 2019-06-30 | -$256.37M 10-Q · filed 2019-07-29 |
| 2019-03-31 | -$213.58M 10-Q · filed 2019-05-03 |
| 2018-12-31 | -$184.60M 10-K · filed 2020-03-02 |
| 2018-09-30 | -$159.09M 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$141.12M 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$126.71M 10-Q · filed 2018-05-14 |
| 2017-12-31 | -$110.25M 10-K · filed 2019-03-08 |
| 2017-09-30 | -$99.72M 10-Q · filed 2017-11-14 |
| 2016-12-31 | -$76.54M 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |